Given the results of the xenograft studies with melanoma, and now breast cancer, it seems reasonable to speculate that the greatest benefit from PaTrin-2-mediated inactivation of MGMT might be seen in tumours with the highest levels of MGMT expression and inherent resistance to temozolomide. This evidence concerns the gene MGMT and neoplasm.